Skip to content

From AI ambition to operational reality in R&D

Establishing a clear digital baseline to accelerate drug discovery, clinical development, and submission timelines

The why

A mid-sized pharmaceutical company set a clear ambition: accelerate growth and shorten submission timelines across R&D. Leadership wanted to harness AI and digital across target identification, molecule discovery, clinical trial design, and real-world evidence.

However, in a rapidly changing AI and digital landscape, translating aspiration into operational impact required clarity on where the R&D organisation stood. The goal was clear, the baseline was not.

The challenge

Digital maturity varied widely across R&D. Clinical Development had established biometrics capabilities and data infrastructure, while parts of Research and Pharmacovigilance relied on fragmented systems and dispersed expertise. AI initiatives in areas such as molecule discovery and protocol optimisation were emerging, but largely ad hoc. There was no shared baseline across strategy, governance, data architecture, talent, and ways of working to guide prioritisation and scalable investment.

How we helped

We benchmarked digital maturity across the R&D value chain against established industry standards, covering Strategy & Vision, Technology & Data Infrastructure, and Organisation & Talent. In addition, we carried-out deep-dives into each function, incl. Research, Clinical Development, and Pharmacovigilance processes. Through structured workshops with functional teams and R&D leadership, we identified capability gaps, resource constraints, and scalability barriers, and translated them into targeted initiatives designed to address these barriers and enable stronger pipeline impact, shorter cycle times, and improved submission readiness.

Outcome

What moved the needle

The assessment worked because it was grounded in operational reality.
A framework built for the client’s R&D context We developed our approach and digital maturity framework to fit the client’s portfolio, organisational size, and growth ambition. We worked directly with scientific and clinical teams to anchor the analysis in real workflows, from target validation to submission planning.
From maturity assessment to R&D decisions Strong engagement of R&D leadership ensured that findings translated into decisions on priorities, governance, and resource allocation. This allowed to move beyond a maturity score, into a decision-making process for scaling AI and digital across R&D.
Partner

Jonas T. Karlsen, Ph.D.

Jonas is a life science strategist supporting executives drive progress across the value chain. He is an expert in bridging strategy and execution via global operating model design and transformation rooted in strategic objectives. He engages with structured top-down thinking and a pragmatic and collaborative approach to mobilise organizations and make things happen.

Jonas holds a Ph.D. in biophysics from the Technical University of Denmark, DTU, and further studied at California Institute of Technology. Recipient of the Ministry of Sciences Elite Research Award.

Selected experience

  • Ecosystem integration and external innovation pipeline
  • Lab of the future capability building and operating model design
  • Global clinical operating model design and transformation
  • Pre-launch strategy for cardiometabolic TA development

 

team-portrait-jonas-tobias-karlsen-4x5-1200x1500